Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study
Lisocabtagene maraleucel (liso-cel) yields a median overall survival of 27.5 months in relapsed or refractory large B-cell lymphoma (R/R LBCL) patients.
Disease-specific survival (DSS) estimates at five years show even higher rates, suggesting sustained control of lymphoma-related mortality.
Long-term follow-up reveals no new safety concerns, with low rates of late severe infections and second primary malignancies, underscoring a favorable safety profile.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
